SH Healthcare Investment Reports 21.95% Stake in NGeneBio After 3:1 Reverse Split

SH Healthcare Investment No.1 Association reported a new ownership of 1,961,926 shares representing about 21.95% of NGeneBio, acquired through share purchase and third-party allotment and subsequently adjusted by a 3:1 reverse stock split effective June 25, 2026.
The filer acknowledged a delayed submission of the major shareholder ownership report due to administrative oversight, stating that related disclosure procedures had been previously completed and that internal controls would be strengthened.
The capital reduction via reverse split decreased total outstanding shares from 26,809,750 to 8,936,583 without altering existing shareholders' ownership percentages, representing a routine share consolidation with no fundraising or dividend implications.
[AI Summary]NGeneBio's 3:1 reverse split is interpreted as a share consolidation likely aimed at boosting the stock price rather than improving financial structure, with current market capitalization around 1,975 billion KRW based on a share price of 737 KRW. SH Healthcare's 21.95% stake appears to be a passive holding with no disclosed plans for additional funding or business expansion, resulting in a neutral impact on shareholder value.